Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
August 10, 2015 – 1:55 pm
Inovio Pharmaceuticals today announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. Under the agreement, MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70 percent of cervical pre-cancers and cancers. MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging evidence suggests that the benefits from immuno-oncology molecules, such as those in MedImmune's portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells.
August 7, 2015 – 9:33 am
An increasing number of studies testing gene therapies are showing promise for treating a wide range of conditions, including cystic fibrosis. Normally in these studies, genes are injected into cells using a virus, however, scientists recently tested a new method of delivering DNA to the faulty CFTR gene in CF through what is called a cationic liposome, a fatty container that can deliver DNA directly to a cell. Results from a Phase 2 efficacy study testing this non-viral CFTR gene therapy for cystic fibrosis appeared in the July 3rd issue of the Lancet Respiratory Medicine, showing promise as a future, novel therapeutic approach for CF.
August 3, 2015 – 4:03 pm
Gene therapy could be more effective than existing treatments for botulism, a rare paralytic illness caused by a nerve toxin, according to an infectious disease researcher at Cummings School. The new approach might also be able to be used to treat other more common infections, such as E. coli food poisoning and the hospital-acquired superbug known as Clostridium difficile. Botulism is caused by a toxin produced by the soil-borne bacterium C. botulinum. People typically get sick when they eat improperly preserved or canned food. Despite the relatively small number of botulism poisoning cases in the U.S., globally there is a serious concern that the toxin—the most potent one known—can be produced easily and inexpensively as a bioterrorism weapon.
July 22, 2015 – 11:01 am
Each year, scientists create an influenza (flu) vaccine that protects against a few specific influenza strains that researchers predict are going to be the most common during that year. Now, a new study shows that scientists may be able to create a 'universal' vaccine that can provide broad protection against numerous influenza strains, including those that could cause future pandemics. The study appears in mBio, the online open-access journal of the American Society for Microbiology.
July 16, 2015 – 1:29 pm
An exciting new study published in Science Translational Medicine has successfully used a gene therapy technique to regenerate partial hearing in deaf mice. It’s at once an important step toward treatment of genetic forms of deafness in humans, and more general proof that gene therapy is well on its way to being a powerful part of modern medicine. It’s important to understand the causes of the particular type of genetic deafness addressed in this study. A simple defect in the gene for transmembrane channel-like protein 1 (TMC1) prevents the tiny, crucial hairs of the cochlea from being able to create electrical impulses at the appropriate time, stimulating the auditory cortex of the brain and causing the perception of sound. This specific problem is reportedly responsible for some 4-8% of cases of genetic deafness — but importantly it does not otherwise impede the development or overall health of the cochlear hairs themselves.
July 10, 2015 – 10:23 am
Researchers have restored hearing in mice with two versions of a genetic mutation that, in humans, causes gradual hearing loss during childhood. The successful work with mice is focused on a gene critical to hearing, TMC1, which encodes a protein that allows physical stimulation of "hairs" in the ear to be translated into sounds understood by the brain. Two types of genetic mutations, one recessive, with the gene deleted, and one dominant, with an altered amino acid, lead to what accounts for 4 to 8 percent of genetic deafness cases. The recessive mutation, which is more common, causes hearing loss by the time a child is 2 years old. The dominant version progressively causes children to lose their hearing starting around 10 or 15 years old.
July 7, 2015 – 11:08 am
The study was carried out by the UK Cystic Fibrosis Gene Therapy Consortium, a group of scientists and clinical teams from Imperial College London, the Universities of Oxford and Edinburgh. It involved 116 patients aged 12 and over who received monthly doses of either the therapy or the placebo for one year. Patients who received therapy showed a significant but modest benefit in lung function compared with those receiving a placebo. The trial is the first to show that repeated doses of gene therapy can have a meaningful effect on the disease, and change the lung function of patients. However, the team say more research is needed to improve the effectiveness before the therapy will be suitable for clinical use.
July 2, 2015 – 9:51 am
Creative Diagnostics, the global diagnostics service and product supplier, is pleased to announce its launch of custom antibody production service based on DNA immunization technology. This DNA immunization technology allows high success rate in generation of high-affinity antibodies recognizing difficult-to-express proteins in their native confirmation, such as GPCRs, ion channels and other multiple membrane spanning proteins. Genetic immunization is an attractive approach to generate antibodies because native proteins are expressed in vivo with normal post-transcriptional modifications, avoiding time-consuming and costly antigen isolation or synthesis. And DNA Immunization technology is a powerful tool to aid in custom antibody production against membrane proteins, other problematic antigens, as well as early DNA vaccine development studies. The unique antibody development approach involves direct immunization of host animals with plasmid DNA encoding the target protein of interest.
July 1, 2015 – 9:52 am
The first four patients in Canada’s only gene therapy trial for blindness say their vision has improved. All four of the Edmonton-area men have choroideremia, an inherited disorder that usually leads to legal blindness by the age of 40. Ken Ross, 43, underwent the procedure on his right eye on May 25, after what he describes as decades of “looking through a pinhole.” He says when doctors removed the bandage two days later the room seemed instantly brighter. And the view outside was better than ever.
June 26, 2015 – 9:37 am
The DNA vaccine segment of the animal vaccines market accounted for the highest growth in veterinary vaccine technology during 2014. Continued current innovation in the field seems likely to continue to drive this trend and thus diversify the animal vaccines market in general. DNA vaccines, particularly in the current animal vaccine market, offer various advantages over more traditional vaccination approaches. It enhances the immune systems response via an uptake in the overall quality and extent from the body, as well as carrying a stronger safety record than other applied veterinary approaches. It has been proven to combat both infectious diseases and malignant cancerous forms, breaking the tolerance these cancerous cells hold in the animal's body, which is a key focus for the vaccination development companies moving forward. With Dr Niranjan Sardesai of Inovio Pharmaceuticals declaring that the past ten years has been potentially the 'decade of DNA vaccines', perhaps exploitation of their cost-effectiveness will also contribute to a continued growth in CAGR.